Different fracture risk profile in patients treated with anti-osteoporotic drugs in real-life

  • G. Adami | adami.g@yahoo.com Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Verona, Italy.
  • A. Giollo Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Verona, Italy.
  • M. Rossini Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Verona, Italy.
  • G. Orsolini Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Verona, Italy.
  • C. Benini Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Verona, Italy.
  • O. Viapiana Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Verona, Italy.
  • D. Gatti Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Verona, Italy.
  • A. Fassio Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Verona, Italy.

Abstract

In this retrospective study, we intended to investigate the baseline fracture risk profile in patients who started treatment with different anti-osteoporotic medications. We analyzed retrospectively the fracture risk calculated with DeFRA, a validated FRAX derived tool, in women who started an anti-osteoporotic treatment from 2010 to 2017. We analyzed baseline data of 12,024 post-menopausal women aged over 50 years. Teriparatide initiators had a baseline 10-year risk of major osteoporotic fracture of 82.1% with a Standard Deviation (SD) of 66.5%. Denosumab initiators and zoledronic acid initiators had a greater 10-year baseline risk of fracture (54.3%, SD 46.5% and 47.0%, SD 42.0 respectively) than patients initiated on alendronate (24.9%, SD 34.6%) and patients initiated on risedronate (23.9%, SD 24.1%). Using DeFRA, a FRAX™ derived tool, we showed significantly different fracture risk profiles in women who were started on various therapeutic agents for the treatment of osteoporosis in routine clinical practice.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2020-07-23
Info
Issue
Section
Articles
Keywords:
Risk of fracture, anti-osteoporotic medications
Statistics
  • Abstract views: 116

  • PDF: 69
How to Cite
Adami, G., Giollo, A., Rossini, M., Orsolini, G., Benini, C., Viapiana, O., Gatti, D., & Fassio, A. (2020). Different fracture risk profile in patients treated with anti-osteoporotic drugs in real-life. Reumatismo, 72(2), 71-74. https://doi.org/10.4081/reumatismo.2020.1267